Please login to the form below

Not currently logged in
Email:
Password:

GSK gets EU nod for sarcoma drug Votrient

EMA lends further momentum to cancer drug

GlaxoSmithKline (GSK) has been granted a new indication for its fast-growing cancer drug Votrient in the EU, with the European Medicines Agency (EMA) giving the go-ahead for its use in soft tissue sarcoma patients.

Votrient (pazopanib), once-daily oral angiogenesis inhibitor, was first approved in 2009 for treating kidney cancer and is among GSK's fastest-growing new products, with sales rising 87 per cent to £72m ($112m) in the first half of the year.

One of the main drivers for that increase was approval for the soft tissue sarcoma indication in the US, despite the fact that the cancer is relatively rare. The EU registration will lend additional momentum to the product.

Specifically, Votrient has been cleared for the treatment of adult patients with advanced soft tissue sarcoma who have received prior chemotherapy or have progressed within 12 months of adjuvant therapy.

In Europe, it is estimated that this type of sarcoma represents an average of 5 out of 100,000 new cancer diagnoses a year.

"The approval of Votrient for this diverse group of tumours marks progress for patients who have seen few new treatment options in decades," commented Dr Paolo Paoletti, president of GSK's oncology business unit.

Votrient is also benefitting commercially from the failure of Merck & Co/Ariad's rival sarcoma therapy Taltorvic (ridaforolimus), which was rejected by the FDA earlier this year as maintenance therapy for patients with metastatic soft tissue sarcoma or bone sarcoma.

Analysts polled by Thomson Reuters have forecast global peak sales of around $500m in 2016 for Votrient, with possible upside if the drug proves effective in ongoing studies in other cancers.

GSK has also been testing Votrient for ovarian, breast and non-small cell lung cancer, as well as for age-related macular degeneration.

8th August 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Guerilla Communications

Guerilla is a fully integrated marketing communications and branding agency with offices in Newcastle Upon Tyne and London. They offer...

Latest intelligence

Easier access to medicines in the UK?
Cutting through the NICE value-based assessment consultation to find out what’s at stake...
Exploring MINT: Part 3 - Nigeria
In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria....
BL_Where_Now_20140721_CoverImage.jpg
3 Steps to Navigating Multichannel in Healthcare
You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign....